Nulyn Science cultivates an environment that inspires creativity, rational risk management, and draws on decades of IP and development experience.
Postoperative cognitive dysfunction (POCD) is a common form of neurocognitive impairment that develops following major surgery. It is estimated that up to 40% of surgical patients over the age of 65 experience symptoms of POCD, half of whom never recover.
NS-001 is a small organic molecule that efficiently crosses the blood brain barrier and inhibits neuroinflammation. It has a long record of safety and efficacy in other indications.
Pre-clinical research has shown that a single preoperative dose of NS-001 prevents the onset of POCD in a standard mouse model. Given its existing safety record, Nulyn Science is currently organizing a Phase 2 trial of NS-001 to explore its efficacy in humans.
The prevalence of Type 2 Diabetes has increased more than four-fold in the last 40 years. However, increased prevalence has not led to improved health outcomes. In fact, in 2021 the mortality rate for this disease increased by 3%, representing 6.7 million diabetes related deaths. Clearly, new treatments of Type 2 Diabetes are urgently needed.
NS-002 is a steroidal anti-glucocorticoid with a decades-long safety and efficacy record in other indications.
In a randomized, double-blind, placebo controlled clinical trial, the GR blockade effect of NS-002 significantly improved insulin sensitivity. To further demonstrate the efficacy of NS-002 as a treatment for Type 2 Diabetes, Nulyn Science is currently organizing a Phase 2 trial.
